These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18954626)

  • 21. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Martel C; Granger CB; Ghitescu M; Stebbins A; Fortier A; Armstrong PW; Bonnefoy A; Theroux P
    Am Heart J; 2012 Jul; 164(1):43-51. PubMed ID: 22795281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines).
    Parikh SV; de Lemos JA; Jessen ME; Brilakis ES; Ohman EM; Chen AY; Wang TY; Peterson ED; Roe MT; Holper EM;
    JACC Cardiovasc Interv; 2010 Apr; 3(4):419-27. PubMed ID: 20398870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study.
    Fattouch K; Bianco G; Speziale G; Sampognaro R; Lavalle C; Guccione F; Dioguardi P; Ruvolo G
    Eur J Cardiothorac Surg; 2007 Aug; 32(2):326-32. PubMed ID: 17576071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.
    ten Berg JM; van 't Hof AW; Dill T; Heestermans T; van Werkum JW; Mosterd A; van Houwelingen G; Koopmans PC; Stella PR; Boersma E; Hamm C;
    J Am Coll Cardiol; 2010 Jun; 55(22):2446-55. PubMed ID: 20510211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study.
    Mentzer RM; Bartels C; Bolli R; Boyce S; Buckberg GD; Chaitman B; Haverich A; Knight J; Menasché P; Myers ML; Nicolau J; Simoons M; Thulin L; Weisel RD;
    Ann Thorac Surg; 2008 Apr; 85(4):1261-70. PubMed ID: 18355507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction.
    Armstrong PW; Mahaffey KW; Chang WC; Weaver WD; Hochman JS; Theroux P; Rollins S; Todaro TG; Granger CB;
    Am Heart J; 2006 Apr; 151(4):787-90. PubMed ID: 16569534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial.
    Mehta RH; Kaul P; Lopes RD; Patel MR; Zheng Y; Pieper KS; Welsh RC; Armstrong PW; Granger CB
    Am Heart J; 2012 May; 163(5):797-803. PubMed ID: 22607857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic C5-complement suppression reduces blood loss during on-pump cardiac surgery.
    Chen JC; Rollins SA; Shernan SK; Boyce S; Allen K; Wallace A; Malloy KJ; Eng JS; Colman RW; Fitch JC;
    J Card Surg; 2005; 20(1):35-41. PubMed ID: 15673408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.
    De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS
    Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
    Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
    Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study.
    Dudek D; Dziewierz A; Widimsky P; Bolognese L; Goldstein P; Hamm C; Tanguay JF; LeNarz L; Miller DL; Brown E; Ten Berg J; Montalescot G;
    Am Heart J; 2015 Nov; 170(5):1025-1032.e2. PubMed ID: 26542513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does Timing of Coronary Artery Bypass Surgery Affect Early and Long-Term Outcomes in Patients With Non-ST-Segment-Elevation Myocardial Infarction?
    Davierwala PM; Verevkin A; Leontyev S; Misfeld M; Borger MA; Mohr FW
    Circulation; 2015 Aug; 132(8):731-40. PubMed ID: 26304664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Alhadramy O; Westerhout CM; Brener SJ; Granger CB; Armstrong PW;
    Am Heart J; 2010 May; 159(5):899-904. PubMed ID: 20435202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study).
    Rusnak JM; Kopecky SL; Clements IP; Gibbons RJ; Holland AE; Peterman HS; Martin JS; Saoud JB; Feldman RL; Breisblatt WM; Simons M; Gessler CJ; Yu AS
    Am J Cardiol; 2001 Sep; 88(5):482-7. PubMed ID: 11524054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction.
    Roe MT; Li S; Thomas L; Wang TY; Alexander KP; Ohman EM; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):323-32. PubMed ID: 23652734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.